Evidence map›Paper›PMID 36142881›Full record

ReviewInternational journal of molecular sciences2022

Mesenchymal Stem Cell-Derived Exosomes: A Promising Therapeutic Agent for the Treatment of Liver Diseases.

Yi Ding, Qiulin Luo, Hanyun Que, Nan Wang, Puyang Gong, Jian Gu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Frontiers in pharmacology · 2026
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yi DingCollege of Pharmacy, Southwest Minzu University, No. 16, South 4th Section, First Ring Road, Chengdu 610041, China.
Qiulin LuoCollege of Pharmacy, Southwest Minzu University, No. 16, South 4th Section, First Ring Road, Chengdu 610041, China.
Hanyun QueCollege of Pharmacy, Southwest Minzu University, No. 16, South 4th Section, First Ring Road, Chengdu 610041, China.
Nan WangCollege of Pharmacy, Southwest Minzu University, No. 16, South 4th Section, First Ring Road, Chengdu 610041, China.
Puyang GongCollege of Pharmacy, Southwest Minzu University, No. 16, South 4th Section, First Ring Road, Chengdu 610041, China.
Jian GuCollege of Pharmacy, Southwest Minzu University, No. 16, South 4th Section, First Ring Road, Chengdu 610041, China.

Funding

National Natural Science Foundation of China 82174083the Excellent Student Training Project of the Central Universities' Basic Research Business Fund 2021NYYXS100
6 · The paper itself

Abstract

Liver disease has become a major global health and economic burden due to its broad spectrum of diseases, multiple causes and difficult treatment. Most liver diseases progress to end-stage liver disease, which has a large amount of matrix deposition that makes it difficult for the liver and hepatocytes to regenerate. Liver transplantation is the only treatment for end-stage liver disease, but the shortage of suitable organs, expensive treatment costs and surgical complications greatly reduce patient survival rates. Therefore, there is an urgent need for an effective treatment modality. Cell-free therapy has become a research hotspot in the field of regenerative medicine. Mesenchymal stem cell (MSC)-derived exosomes have regulatory properties and transport functional "cargo" through physiological barriers to target cells to exert communication and regulatory activities. These exosomes also have little tumorigenic risk. MSC-derived exosomes promote hepatocyte proliferation and repair damaged liver tissue by participating in intercellular communication and regulating signal transduction, which supports their promise as a new strategy for the treatment of liver diseases. This paper reviews the physiological functions of exosomes and highlights the physiological changes and alterations in signaling pathways related to MSC-derived exosomes for the treatment of liver diseases in some relevant clinical studies. We also summarize the advantages of exosomes as drug delivery vehicles and discuss the challenges of exosome treatment of liver diseases in the future.

Indexed as

End Stage Liver DiseaseExosomesLiver DiseasesMesenchymal Stem CellsHumansRegenerative Medicineexosomesliver diseasesmesenchymal stem cellsregenerationtherapy

Identifiers

PMID36142881
PMCPMC9502508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.